Introducción
The FDA has expanded the indications for the B-cell depleter obinutuzumab (Gazyva) to include idiopathic nephrotic syndrome, marking the first new treatment option for this rare kidney disease in over 50 years.
¿Qué es la enfermedad?
Idiopathic nephrotic syndrome is an autoimmune condition affecting the kidneys, leading to significant protein loss in the urine and resulting in hypoalbuminemia. This condition can cause various complications, including high cholesterol, infections, and blood clots.
Nueva indicación del tratamiento
The injection of obinutuzumab is indicated for patients aged 2 years and older with frequently relapsing or steroid-dependent idiopathic nephrotic syndrome who are in complete remission. This therapy targets B cells to help control disease activity and can produce longer-lasting remissions.
Resultados del estudio clínico
Approval is supported by data from the phase III INShore study, which showed that a higher proportion of participants achieved complete remission at week 52 using obinutuzumab compared to the standard therapy, mycophenolate mofetil (95% vs 73%). Key secondary endpoints also indicated statistically significant benefits with the new treatment.
Perspectivas para los pacientes
The Nephrotic Syndrome Foundation’s president stated that this approval marks a significant shift, allowing patients and families to have renewed hope and expectations for their care.
Eventos adversos y precauciones
No new safety concerns were reported with obinutuzumab in the clinical study. Common side effects include upper respiratory infections and infusion-related reactions. It’s crucial to consider the warnings associated with possible serious infections and other reactions.
Please consult with a healthcare professional for personalized medical advice and treatment options.
Fuente: https://www.medpagetoday.com/nephrology/generalnephrology/123168
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
